According to British Society for Haematology (BSH) guidelines and NICE Clinical Knowledge Summaries (CKS), the primary beneficiaries include: Key patient groups who may require B12 injections include: Pernicious anaemia patients requiring lifelong hydroxocobalamin 1mg intramuscularly every 23 months following initial loading doses Patients with gastrointestinal disorders including those who have undergone gastrectomy or ileal resection, and patients with conditions affecting B12 absorption such as Crohn's disease or coeliac disease Strict vegans and vegetarians though oral supplementation is usually sufficient unless malabsorption is present Elderly patients who may have reduced gastric acid production affecting B12 absorption Patients taking certain medications including metformin (MHRA advises monitoring B12 levels in long-term users, particularly those with risk factors or symptoms), proton pump inhibitors, and H2-receptor antagonists long-term [6] Individuals with neurological symptoms such as paraesthesia, ataxia, or cognitive impairment related to B12 deficiency Pregnant women with confirmed deficiency (hydroxocobalamin for malabsorption
Aliquot immediately into single-use volumes and store at -20C
I still have tinnitus 6 months out that while not as bad, still can be bothersome early morning
Note: The Food and Drug Administration (FDA) has not approved Ozempic for weight loss, but some healthcare professionals may prescribe it off-label
doi: 10.1007/s12975-020-00863-4
This review highlights NAD+ as a central regulator of energy metabolism, mitochondrial function, and cellular repair, demonstrating that age-related declines in NAD+ may contribute to chronic disease, while supplementation with NAD+ boosters shows potential for reducing age-related decline and disease
